Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect

Molecular Therapy

Volumn 7, Issue 6, 2003, Pages 748-754

  Fu, Xinping ^a,c   Tao, Lihua ^a,c   Jin, Aiwu ^a   Vile, Richard ^b   Brenner, Malcolm K ^a   Zhang, Xiaoliu ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b MAYO CLINIC   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Fusogenic membrane glycoprotein; Herpes simplex virus; Late viral promoter; Liver cancer; Oncolytic

Indexed keywords

MEMBRANE PROTEIN; ONCOLYTIC VIRUS; VIRUS DNA; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; GENE ACTIVITY; GENE EXPRESSION; GENE INSERTION; GENETIC CODE; GENETIC MANIPULATION; GIBBON LEUKEMIA VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOSIS; MOUSE; NONHUMAN; PROMOTER REGION; SOLID TUMOR; TUMOR CELL;

ALOCASIA MACRORRHIZOS; ANIMALIA; DNA VIRUSES; GIBBON APE LEUKEMIA VIRUS; HERPES; HYLOBATES SP.; SIMPLEXVIRUS;

EID: 0037598911     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00092-3     Document Type: Article

References (27)

1. Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., and Coen, D. M. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854-856.
2. Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1: 938-943.
3. Toda, M., Rabkin, S. D., and Martuza, R. L. (1998). Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum. Gene Ther. 9: 2177-2185.
4. Walker, J. R., et al. (1999). Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum. Gene Ther. 10: 2237-2243.
5. Toyoizumi, T., et al. (1999). Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum. Gene Ther. 10: 3013-3029.
6. Coukos, G., et al. (1999). Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin. Cancer Res. 5: 1523-1537.
7. Carroll, N. M., Chiocca, E. A., Takahashi, K., and Tanabe, K. K. (1996). Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann. Surg. 224: 323-329, discussion 329-330.
8. Pawlik, T. M., et al. (2000). Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res. 60: 2790-2795.
9. Sundaresan, P., Hunter, W. D., Martuza, R. L., and Rabkin, S. D. (2000). Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J. Virol. 74: 3832-3841.
10. Todo, T., et al. (2000). Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol. Ther. 2: 588-595.
11. Markert, J. M., et al. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7: 867-874.
12. Rampling, R., et al. (2000). Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7: 859-866.
13. Kirn, D. (2001). Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin. Biol. Ther. 1: 525-538.
14. Nemunaitis, J., et al. (2001). Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19: 289-298.
15. Kramm, C. M., et al. (1997). Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8: 2057-2068.
16. Bateman, A., et al. (2000). Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res. 60: 1492-1497.
17. Fielding, A. K., et al. (2000). A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display. Hum. Gene Ther. 11: 817-826.
18. Januszeski, M. M., Cannon, P. M., Chen, D., Rozenberg, Y., and Anderson, W. F. (1997). Functional analysis of the cytoplasmic tail of Moloney murine leukemia virus envelope protein. J. Virol. 71: 3613-3619.
19. Higuchi, H., et al. (2000). Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy. Cancer Res. 60: 6396-6402.
20. Diaz, R. M., et al. (2000). A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther. 7: 1656-1663.
21. Weir, J. P. (2001). Regulation of herpes simplex virus gene expression. Gene 271: 117-130.
22. Stavropoulos, T. A., and Strathdee, C. A. (1998). An enhanced packaging system for helper-dependent herpes simplex virus vectors. J. Virol. 72: 7137-7143.
23. Fu, X., and Zhang, X. (2002). Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res. 62: 2306-2312.
24. Saeki, Y., et al. (1998). Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum. Gene Ther. 9: 2787-2794.
25. Guzowski, J. F., and Wagner, E. K. (1993). Mutational analysis of the herpes simplex virus type 1 strict late UL38 promoter/leader reveals two regions critical in transcriptional regulation. J. Virol. 67: 5098-5108.
26. Zhang, X., Efstathiou, S., and Simmons, A. (1994). Identification of novel herpes simplex virus replicative intermediates by field inversion gel electrophoresis: implications for viral DNA amplification strategies. Virology 202: 530-539.
27. Schang, L. M., Phillips, J., and Schaffer, P. A. (1998). Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J. Virol. 72: 5626-5637.